Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
On March 20, 2025, Prasad Raju, the Chief Financial Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), executed several transactions involving the company’s common shares. According to a recent SEC filing, Raju sold 2,197 shares at a price of $41.23 each, resulting in a total transaction value of $90,582.
The filing also detailed the acquisition of 6,250 common shares through the vesting of restricted stock units (RSUs) on March 20, 2025. This acquisition did not involve any exchange of cash, as each RSU represents a right to receive one common share of CRISPR Therapeutics. Following these transactions, Raju holds 16,767 shares directly. With the company’s next earnings report scheduled for May 12, 2025, investors tracking insider movements can access comprehensive analysis through InvestingPro’s detailed research reports.
The sale of shares was conducted to cover tax withholding obligations related to the vesting of RSUs, as mandated by the company’s RSU Settlement Policy, and does not represent a discretionary trade by Raju. Despite current unprofitability, CRISPR maintains strong liquidity with a current ratio of 22.07, indicating robust short-term financial health.
In other recent news, CRISPR Therapeutics has seen several analyst updates and developments. Evercore ISI upgraded the company’s stock from In Line to Outperform, raising the price target to $99 from $60, driven by optimism about upcoming catalysts and the potential of in vivo programs CTX320 and CTX310. Citi analysts maintained a Buy rating but adjusted the price target to $82, emphasizing the progress of Casgevy with over 50 treatment centers activated globally. However, Stifel analysts took a more cautious approach, reducing their price target to $49 while maintaining a Hold rating, citing concerns about the market uptake of Casgevy. TD Cowen also revised their stance, upgrading CRISPR Therapeutics from Sell to Hold with a price target of $35, noting reduced downside risk for the company’s shares.
CRISPR Therapeutics’ pipeline developments are drawing attention, with expectations for initial in-vivo data for Lp(a) and ANGPTL3, as well as updates on CTX211 for type 1 diabetes in 2025. The company reported growth in Casgevy cell collections, with over 50 new collections in the final nine weeks of the fourth quarter. Analysts are particularly interested in the potential impact of the company’s in vivo programs on atherosclerotic cardiovascular disease. The firm’s robust cash position of $1.9 billion is seen as a strong support for its research and development activities. These recent developments highlight the varied analyst perspectives on CRISPR Therapeutics’ future prospects and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.